ICER Announces Final Evidence Report for FibroGen’s Roxadustat, Uncertainties Linger
ICER has released a final evidence report for roxadustat, along with policy recommendations. Cardiovascular risks were one of the concerns [...]
ICER To Review Hypertrophic Cardiomyopathy Drug
ICER has announced its intention to review mavacamten, a drug for use in hypertrophic cardiomyopathy. The Draft Scoping Document is [...]
ICER Releases Evidence Report on Lupus Nephritis Drugs
ICER has published a new evidence report on two drugs for use in lupus nephritis patients. FDA-approved voclosporin and belimumab [...]
Whitepaper on Tailoring Your Novel Therapeutic to ICER Standards
ICER (the Institute for Clinical and Economic Review) is an independent nonprofit organization dedicated to the fair evaluation of prescription [...]
ICER Releases Evidence Report on Multiple Myeloma Therapies
ICER has released a new evidence report on CAR T-cell therapies to treat multiple myeloma. All three therapeutics (idecabtagene vicleucel, [...]
Understanding ICER’s New Life Years Metric
ICER (the Institute for Clinical and Economic Review) revealed a new metric in 2018: evLYG (equal value of life years [...]
Comparing ICER and IVI in Shifting Value-Based Reimbursement Landscape
The US healthcare system is transitioning from a volume- to a value-based reimbursement payment structure. Assigning value continues to be [...]
Aurinia Announces ICER’s Favorable Review for Lupus Nephritis Drug
Aurinia Pharmaceuticals announced that ICER (the Institute for Clinical and Economic Review) has released a positive Evidence Report for its [...]
ICER Announces New Governance Board Members in Push to Improve Drug Pricing and Health Equity
ICER (the Institute for Clinical and Economic Review) has announced the election of two members to its Governance Board: Joy [...]
Will States Look to ICER Reports in Legislative Measures to Regulate Drug Prices?
High drug prices are a national crisis. Policymakers in three different states (Washington, Maine, and Hawaii) have introduced price control [...]
ICER Adds Members to Three Appraisal Councils to Boost Evidence Reviews
ICER (the Institute for Clinical and Economic Review) has added members to three independence appraisal councils: Midwest CEPAC (Midwest Comparative [...]
ICER to Investigate Treatments for Autoimmune Disease Myasthenia Gravis
ICER will determine the efficacy and economic outcomes of two treatments for autoimmune disease Myasthenia Gravis where neuromuscular junctions are [...]
New CMS Director Could Indicate Shift in Medicare Prescription Drug Pricing Policy
Arielle Woronoff is joining the new administration as director of the CMS Office of Legislation. She previously held worked in [...]
ICER Unsatisfied With Fibrogen’s Roxadustat Evidence; FDA Calls Advisory Committee
ICER held a meeting on February 11th, during which its independent appraisal committee agreed that it was not possible to [...]
How Will Emphasis on Patient Centricity and ICER Influence Payer Decisions?
The 21st Century Cures Act, as well as FDA guidelines, are putting a spotlight on patient centricity—from drug development to [...]
Using RWE to Make Cost Decisions: A New Report
A recent article, published in JMCP (the Journal of Managed Care and Specialty Pharmacy), considers how RWE (real world evidence) can be utilized when making economic decisions. ICER (the Institute for Clinical and Economic Review) has incorporated RWE in making its recommendations, but few other organizations have been as ready to make such a move.
CBO Paper Details Future Impact of ICER
The Congressional Budget Office (CBO) put out a draft of a paper where it notes calculations regarding Medicare drug prices. [...]
How Should COVID-19 Vaccines Be Priced?
The US government has entered into contracts with several pharmaceutical companies to deliver COVID-19 vaccines. Although it is currently not [...]
ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis
Also this morning, we published our Draft Evidence Report assessing the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) [...]
ICER Publishes Evidence Report on Therapies for High Cholesterol
This morning ICER issued the Evidence Report assessing the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol®, [...]
Drug price hikes without new evidence upped spending by $1.2B
The Institute for Clinical and Economic Review (ICER) published its second-ever report on Unsupported Price Increases (UPI) last week, compiled from data [...]
[Podcast] How Doctors Can Be a Part of the Solution
In the final episode of our podcast's inaugural season, neurologist Jason Crowell and ICER's President Steve Pearson discuss what physicians [...]
State Level Action in Response to ICER’s Unsupported Price Increase Report
In ICER’s latest report on Unsupported Price Increases (UPI), we determined that 7 of the 10 costliest US drug-price hikes [...]
Amgen Tops Cost Watchdog’s Price Gougers List
In a top 10 ranking of the most egregious price gougers from 2019, Amgen’s Enbrel topped US cost watchdog ICER’s [...]
ICER Identifies Most Significant 2019 US Drug-Price Hikes
The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription [...]